CLPTNasdaqSurgical & Medical Instruments & ApparatusFiscal year ends December 31
ClearPoint Neuro, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 3, 2026
$9.17+0.10 (+1.10%)
Close on Oct 19, 2026
- Market cap
- $276.63M
- P/E (TTM)
- –
- Dividend yield
- –
ClearPoint Neuro statistics
Financials through Jun 30, 2026, price as of Oct 19, 2026, median of Surgical & Medical Instruments & Apparatus companies for comparison
Valuation
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Market Cap | $279.72M | $230.55M |
| Enterprise Value | $300.59M | $202.97M |
| PS Ratio | 6.62 | 3.11 |
| PB Ratio | 25.96 | 3.14 |
Enterprise value
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| EV / Sales | 7.11 | 2.92 |
Income (trailing twelve months)
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Revenue | $42.28M | $102.39M |
| Gross Profit | $26.47M | $60.36M |
| Operating Income | -$31.04M | -$4.31M |
| Pretax Income | -$34.58M | -$2.26M |
| Net Income | -$34.57M | -$6.57M |
| EBITDA | -$30.49M | -$1.98M |
| EPS (Diluted) | -$1.18 | -$0.07 |
Margins
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Gross Margin | 62.6% | 55.1% |
| Operating Margin | -73.4% | -6.04% |
| Pretax Margin | -81.8% | -4.11% |
| Profit Margin | -81.8% | -10.5% |
| EBITDA Margin | -72.1% | -2.67% |
| FCF Margin | -73.9% | -0.30% |
Returns
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Return on Equity (ROE) | -226.5% | -19.2% |
| Return on Assets (ROA) | -46.2% | -13.3% |
| Return on Invested Capital (ROIC) | -126.8% | -4.11% |
| Return on Capital Employed (ROCE) | -40.6% | -9.07% |
Growth
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Revenue Growth (YoY) | 25.9% | 8.85% |
| Revenue Growth (3Y CAGR) | 21.6% | 7.08% |
| Revenue Growth (5Y CAGR) | 23.6% | 11.8% |
Balance sheet
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Cash & Short-Term Investments | $29.36M | $37.33M |
| Total Debt | $50.23M | $72.66M |
| Net Cash (Debt) | -$20.87M | $3.92M |
| Net Cash Per Share | -$0.68 | $0.28 |
| Equity (Book Value) | $10.78M | $57.36M |
| Book Value Per Share | $0.35 | $2.81 |
| Tangible Book Value | -$9.61M | $10.71M |
| Working Capital | $38.62M | $54.64M |
Financial position
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Current Ratio | 4.74 | 2.50 |
| Quick Ratio | 3.66 | 1.54 |
| Debt / Equity | 4.66 | 0.38 |
Cash flow (trailing twelve months)
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Operating Cash Flow | -$30.16M | -$653.46K |
| Capital Expenditures | -$1.11M | -$3.69M |
| Free Cash Flow | -$31.27M | -$835.02K |
| FCF Per Share | -$1.02 | -$0.02 |
Efficiency
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Asset Turnover | 0.57 | 0.59 |
| Inventory Turnover | 2.09 | 2.21 |
| Revenue Per Employee | $245.81K | $322.57K |
| Profits Per Employee | -$200.97K | -$51.88K |
| Employee Count | 172 | 185 |
Dividends and yields
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Earnings Yield | -12.4% | -6.91% |
| FCF Yield | -11.2% | -0.56% |
Shares
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Shares Outstanding | 30,504,200 | 44,856,700 |
| Shares Change (YoY) | 5.24% | 3.35% |
| Shares Change (QoQ) | 1.72% | 0.27% |
| Float | 29,340,500 | 37,097,900 |
| Shares Held by Insiders | 3.82% | 10.6% |
| Shares Held by Institutions | 45.6% | 63.5% |
Taxes
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Income Tax | -$18.00K | $1.52M |
Scores
| Measure | ClearPoint Neuro | Industry median |
|---|---|---|
| Altman Z-Score | -1.79 | 1.95 |
| Piotroski F-Score | 5 | 5 |
| Beneish M-Score | -1.72 | -2.64 |
Calculated by StockData from ClearPoint Neuro's SEC filings and the latest closing price. Hover a measure to see its formula. The grey column is the median of companies in the same industry group (two-digit SIC code); green or red marks a better or worse value than that median.